폐암 (NSCLC)

171개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved171 programs
AntibodyCurated CoreFDABristol Myers SquibbApproved

nivolumab (Opdivo, BMS-936558)

Melanoma, NSCLC, RCC, HCC, MSI-H tumors, and others · PD-1

#PD-1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 1280Status Approved
AntibodyCurated CoreFDAAstraZenecaApproved

durvalumab (Imfinzi, MEDI4736)

NSCLC (Stage III consolidation), SCLC, biliary tract, HCC · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 750Status Approved
AntibodyCurated CoreFDARocheApproved

atezolizumab (Tecentriq, MPDL3280A)

NSCLC, SCLC, HCC, TNBC, urothelial carcinoma, and others · PD-L1

#PD-L1#Antibody#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 693Status Approved
ADCCurated CoreFDADaiichi SankyoDXd (exatecan derivative, t…Approved

datopotamab deruxtecan (Datroway, DS-1062, Dato-DXd, datopotamab-deruxtecan-dlnk)

HR+/HER2− breast cancer; EGFR-mutated non-small cell lung cancer · TROP2

#TROP2#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 50Status Approved
AntibodyCurated CoreFDAAmgenApproved

tarlatamab (Imdelltra, AMG 757, tarlatamab-dlle)

Extensive-stage small cell lung cancer after platinum-based chemotherapy · DLL3 × CD3

#DLL3CD3#Antibody#Approved#FDA-approved#BioJungboMoa-pick+4
Trials 39Status Approved
ADCStandard DatabaseFDAstaleDaiichi SankyoApproved

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Approved#FDA-approved#antibody-drug-conjugate+3
Trials 24Status Approved
ADCCurated CoreFDAstaleGenmabApproved

Tisotumab Vedotin (Tisotumab Vedotin)

Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung · Solid Malignancies

#SolidMalignancies#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 14Status Approved
ADCCurated CoreFDAAbbVieMMAE (microtubule inhibitor)Approved

telisotuzumab vedotin (Emrelis, ABBV-399, Teliso-V, telisotuzumab-vedotin-tllv)

Previously treated locally advanced or metastatic non-squamous NSCLC with high c-Met protein overexpression · c-Met

#c-Met#ADC#Approved#FDA-approved#BioJungboMoa-pick+5
Trials 12Status Approved
AntibodyLimited DatastaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#Popular#monoclonal-antibody+3
Trials 155Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyo Co., Ltd.Phase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+3
Trials 149Status Recruiting
ADCStandard DatabasestaleDaiichi Sankyo Co., Ltd.deruxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#Popular#antibody-drug-conjugate+4
Trials 148Status Recruiting
AntibodyLimited DatastaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 141Status Active
AntibodyLimited DatastaleMerck KGaAPhase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#Popular#monoclonal-antibody+4
Trials 138Status Active
ADCStandard DatabasestaleDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#Popular#antibody-drug-conjugate+4
Trials 124Status Recruiting
AntibodyCurated CorestaleEli Lilly and CompanyPhase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#BioJungboMoa-pick#Popular+5
Trials 117Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

Durvalumab (MEDI4736, MEDI4736 (Durvalumab))

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Tumors

#AdvancedSolidTumors#Antibody#Phase3#Popular#monoclonal-antibody+3
Trials 94Status Active
AntibodyLimited DatastaleRochePreclinical

MPDL3280A (Atezolizumab, Atezolizumab (MPDL3280A))

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Preclinical#Popular#monoclonal-antibody+1
Trials 60Status Active
AntibodyLimited DatastaleBristol Myers SquibbPhase 2

nivolumab (Opdivo, ipilimumab + nivolumab)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#Popular#monoclonal-antibody+2
Trials 60Status Recruiting
ADCLimited DatastaleMerck Sharp & Dohme LLCGovitecan in gynecologic ma…Phase 3

sacituzumab govitecan (Trodelvy, Sacituzumab tirumotecan)

Non-small Cell Lung Cancer; Solid Tumors · Endometrial Cancer

#EndometrialCancer#ADC#Phase3#Popular#antibody-drug-conjugate+5
Trials 57Status Recruiting
AntibodyLimited DatastaleAstraZenecaPhase 3

durvalumab (Imfinzi, MEDI4736, MEDI4736 (Durvalumab) + Tremelimumab)

Non-Small-Cell Lung Carcinoma NSCLC · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase3#Popular#monoclonal-antibody+2
Trials 56Status Recruiting

1 / 9 pages

← PreviousNext →